Better Health. Better Life.

Title Created Date
M Pharmaceutical Inc. Appoints Mr. William A. Rodgers Jr., of Milton, Georgia to Its Board of Directors 21 February 2017
M Pharmaceutical Inc. Announces Acquisition of Assets from 40 JS LLC 17 February 2017
SeeThruEquity Issues Update on M Pharmaceutical, Inc. 16 February 2017
M Pharmaceutical Inc. Appoints Mr. Gary Thompson President & CEO 13 February 2017
M Pharmaceutical Inc. Provides Strategic Report to Shareholders Highlighting Acquisitions and Product Development 10 February 2017
M Pharmaceutical Inc. Announces Repricing Of Warrants And Options Grant 26 January 2017
M Pharmaceutical Inc. Announces Strategy To Seek Distribution Partners For Their Patented Technologies To Deliver Phytoestrogens For The Treatment Of The Symptoms Of Menopause 24 January 2017
M Pharmaceutical Inc. to Remove Parabens from All Future Products 19 January 2017
M Pharmaceutical Inc. Announces Plans to Actively Seek Partners To Distribute Its Recently Acquired Technologies for Diabetic Neuropathy Relief 18 January 2017
M Pharmaceutical Inc. Announces Plans to Develop a Drug Product for Treatment of Female Sexual Dysfunction 12 January 2017
M Pharmaceutical Inc. Announces Plans on Expanding Distribution of Successful OTC Products 10 January 2017
Canadian Company Buys Turpin Hills Biotech 09 January 2017
M Pharmaceutical Inc. Announces That It Will Simultaneously Commercialize And Market Over-The-Counter C-103, Reformulated Orlistat 06 January 2017
M Pharmaceutical Inc. Enters Into Exclusive Negotiations To Acquire 40J’s LLC 04 January 2017

Drug Treatment Portfolio

Obesity, Weight Management Treatment

C-103 is a novel reformulation of orlistat, patented until 2030 in the U.S.  Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter).  Proven safe and effective in over 100 clinical trials, orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007.  The C-103 reformulation addresses adverse events reported by over 90% of orlistat users. These adverse events have led to the decline in Orlistat sales to approximately $200 million in recent years. 

C-103 is intended to maintain the efficacy of orlistat while minimizing its socially unacceptable adverse events. Unlike other weight loss drugs:

  • Orlistat is not an amphetamine
  • Orlistat does not affect the central nervous system
  • Orlistat is not systemically absorbed
  • Orlistat is the only FDA-approved OTC weight loss drug because of its safety
  • Orlistat is the only FDA-approved weight loss drug for adolescent patients (age 12-18)

Infertility Treatment

ToConceive is an innovative new infertility treatment that offers hope and assistance to the millions of couples worldwide struggling to start a family. Our product is an easy to use topical gel that helps to balance the pH of the vagina and is clinically proven to increases a women’s natural production of transudate (sexual lubrication). This increase in natural transudate is required for successful “Sperm Capacitation” to occur. Without the process of Sperm Capacitation, the sperm would not have the ability to travel the required distance to the ovum or have the appropriate chemical makeup for successful conception to occur.

ToConceive is a women’s health treatment supported by a FDA 510K clearance and is protected by four USPTO patents. ToConceive’s proven ability to increase a woman’s natural production of transudate results in significantly higher success rates for couples trying to conceive, without the added expense, or stress, associated with assisted reproduction treatments.